Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data

21d ago, source: Hosted on MSN

T hursday, eFFECTOR Therapeutics Inc (NASDAQ:EFTR) released topline results from the primary analysis of the Phase 2 KICKSTART trial, which tested tomivosertib or placebo, each combined with Merck ...

eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

22d ago, source: Business Insider

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator ...

eFFECTOR Therapeutics Inc EFTR

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

eFFECTOR Therapeutics Inc. Wt

29d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

EFFECTOR Reports Results Of Phase2 KICKSTART Trial Of Tomivosertib-Pembrolizumab In NSCLC

21d ago, source: Nasdaq

(RTTNews) - eFFECTOR Therapeutics, Inc. (EFTR) announced Thursday topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo ...

eFFECTOR Therapeutics Inc EFTR

8d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

eFFECTOR Therapeutics Inc.

29d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...